KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Gsk (GSK) EPS (Weighted Average and Diluted) (2017 - 2022)

Gsk has reported EPS (Weighted Average and Diluted) over the past 7 years, most recently at -$16580.9 for Q4 2022.

  • For Q4 2022, EPS (Weighted Average and Diluted) fell 1422.61% year-over-year to -$16580.9; the TTM value through Dec 2022 reached -$217.99, down 103.1%, while the annual FY2025 figure was $1.85, 131.26% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2022 was -$16580.9 at Gsk, down from $12201.5 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $12201.5 in Q3 2022 and troughed at -$16580.9 in Q4 2022.
  • A 3-year average of $694.39 and a median of $1811.7 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 100615.73% in 2018 and later plummeted 1422.61% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.05 in 2018, then soared by 2534601.91% to $1253.6 in 2021, then tumbled by 1422.61% to -$16580.9 in 2022.
  • Business Quant data shows EPS (Weighted Average and Diluted) for GSK at -$16580.9 in Q4 2022, $12201.5 in Q3 2022, and $2907.8 in Q1 2022.